Mainsail Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$270K Buy
556
+100
+22% +$44.3K 0.11% 130
2026
Q1
$204K Buy
456
+2
+0.4% +$933 0.09% 109
2025
Q4
$206K Buy
+454
New +$196K 0.09% 100
2025
Q3
Sell
-462
Closed -$206K 93
2025
Q2
$206K Hold
462
0.13% 57
2025
Q1
$224K Buy
+462
New +$215K 0.15% 53
2024
Q4
Sell
-450
Closed -$209K 69
2024
Q3
$209K Hold
450
0.16% 58
2024
Q2
$211K Buy
+450
New +$195K 0.17% 51

Other funds holding VRTX

Mainsail Asset Management's VRTX Position: Q2 2026 in Review

Mainsail Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, buying an estimated $44.3K and bringing the position to 556 shares worth $270K. The position accounts for 0.11% of the portfolio, ranked #130.

Mainsail Asset Management first reported a position in VRTX in Q2 2024 and has held it in 7 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Mainsail Asset Management held 556 shares of Vertex Pharmaceuticals worth $270K as of Q2 2026.
  • Mainsail Asset Management bought 100 Vertex Pharmaceuticals shares in Q2 2026, an estimated $44.3K.
  • Vertex Pharmaceuticals made up 0.11% of Mainsail Asset Management's portfolio in Q2 2026, its #130 holding.
  • Mainsail Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mainsail Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.